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Introduction. Pyogenic granuloma (PG) and peripheral giant-cell granuloma (PGCG) are two of the most common inflammatory
lesions associated with implants; however, there is no established pathway for treatment of these conditions. This paper aims to
illustrate the successful treatment of PG and PGCG and also report a systematic review of the literature regarding the various
treatments proposed.Methods. To collect relevant information about previous treatments for PG and PGCG involving implants we
carried out electronic searches of publications with the key words “granuloma”, “oral”, and “implants” from the last 15 years on the
databases Pubmed, National Library of Medicine’s Medline, Scielo, Scopus, and Cochrane Library. Results. From the electronic
search 16 case reports were found showing excision and curettage as the main successful treatment. As no clinical trials or
observational studies were identified the authors agreed to present results from a review perspective. Conclusion. This is the largest
analysis of PG andPGCGassociatedwith implants published to date.Our reviewwould suggest that PGCGassociatedwith implants
appears to have a more aggressive nature; however the level of evidence is very limited. Further cohort studies with representative
sample sizes and standard outcome measures are necessary for better understanding of these conditions.
1. Introduction
Reactive lesions are characterized as excessive proliferation
of connective tissue as a response to chronic irritation
[1]. Among these types of lesions, those seen in the oral
cavity include pyogenic granuloma (PG), peripheral fibroma,
fibroepithelial hyperplasia, peripheral ossifying fibroma, and
peripheral giant-cell granuloma (PGCG). PG and PGCG
appear to be the ones commonly associated with implants,
as in the past few years multiple case reports have been
published [1, 2].
PG is defined as an inflammatory hyperplasia that usually
appears as a response to irritants, trauma, hormonal changes,
or certain medications [3, 4]. Although classically it is called
PG, amore correct namewould be focal epithelial hyperplasia
since the lesion is not strictly a granuloma or an infection
[3, 4]. Peripheral giant-cell granuloma (PGCG) is considered
a reactive hyperplastic lesion, although its etiology is not
entirely known. It is believed that its pathogenesis includes an
excessive activation of osteoclasts, which is associated with a
proliferation ofmacrophages, and possibly causesmajor bone
resorption [2, 5].
PG is more frequent in women in their 20s, with a ratio
of 3 : 2 [4]. In 75% of cases it occurs in keratinized gingiva,
with location in order of frequency of tongue, lips, and then
buccal mucosa [3, 4]. It is more common in the maxilla than
in the mandible and in anterior as opposed to posterior areas
[4]. In contrast, PGCG usually appears in patients who are
between their 40s and 60s, and it is slightly more frequent in
women and tends to appear more often in the mandible than
in the maxilla (Table 1) [4, 5]. The treatment of these lesions
generally involves eliminating the irritating factors as well
as performing surgical removal [1, 2]. Commonly associated
with periodontal disease, where calculus is the irritating
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Table 1: Summarizing the differential diagnosis between pyogenic granuloma and peripheral giant-cell granuloma.
Pyogenic granuloma Peripheral giant-cell granuloma
Age 20s 40s–60s
Sex Women Women
Localization Anterior maxilla Posterior mandible
Symptomology Asymptomatic Asymptomatic
Color Reddish Reddish-purple
Sessile/with a pedicle Both Both
Bone involvement No Possible
factor, surgical removal along with nonsurgical debridement
is well described in the literature [6].
Implant rehabilitation has become more common in the
last decade and several factors have been studied which could
interferewith osteointegration and longevity [7]. Factors such
as smoking, diabetes, and periodontal disease have been
studied [7–11]. However, with regard to reactive lesions such
as PG and PGCG there is no clear pathway for intervention
or treatment to manage these lesions and maintain healthy
tissue around the implants [7].
The aim of this paper is to demonstrate the successful
management of cases of PG and PGCG associated with
implants and to review the literature for the various treatment
options.
2. Materials and Methods
To collect all relevant information about previous published
treatments for PG and PGCG involving implants, the authors
carried out an electronic search from to January 2000 to
June 2015 (Pubmed Central, National Library of Medicine’s
Medline, Scielo, Scopus, and Cochrane Library) for reac-
tive lesions related to implants (key words: “granuloma”,
“oral”, and “implants”). These articles were obtained, and a
hand search of their bibliographies identified any pertinent
secondary references. This process was repeated until no
further new articles could be identified. The inclusion cri-
teria included clinical trials, cohort studies, case-controlled
studies, case series, and case reports, published in English,
Portuguese, French, and Spanish, which included a clear
description of the treatment employed. The search was lim-
ited to human studies and all articles which did not fit into the
criteriawere excluded.The full papers and abstracts identified
through the search were independently reviewed by all
authors (EJN, RA, AFM, BGM, AED, and JLL) for inclusion
in this systematic review. If there was insufficient information
provided in the abstract or if there was a disagreement
between reviewers, the authors reviewed the full text before
reaching consensus through discussion. Data extraction was
then completed in duplicate by the same independent review-
ers.The following data were collected: study year, gender, age,
location of the implant/PG/PGCG, treatment used, relapse,
follow-up, and histopathology (Table 2).
The author (JLL) prepared data extraction tables and
all authors contributed to summary reports of the selected
journal articles and review of the literature.
The case reports protocol was carried out with patient
informed consent following guidelines according to the
Helsinki Declaration of 1975, as revised in 2000.
3. Results
From the 55 articles initially selected, 39 studies were
excluded as they were related to teeth or not directly related
to implants. All 16 articles selected were case reports; these
ranged from reports of a single case to articles describing up
to a maximum of 3 cases, such that a total of 21 patients were
reported. Of these there were 15 cases of PGCG [2, 5, 9–16, 21]
and 6 of PG [4, 14, 17–20] (Table 2). As no experimental or
observational studies were identified the authors agreed that
it would not be reasonable to critically appraise the quality of
the studies and consequently the results are presented from a
review perspective.
The majority of patients with PGCG were women (3 : 1)
while PG was seen more commonly in males (2 : 1) (Table 2).
The average age of the population who suffered PGCG was
49.6 while for PG it was 50.3. The majority of published cases
of PGCG associated with implants had suffered bone loss
around the implant [2, 5, 11–15], as only 4 of the published
cases of PGCG did not experience bone loss [9, 10, 12, 21]
(26.7%). On the other hand bone loss did not occur in cases
of PG [4, 14, 17–20].
The six cases of PGwere treatedwith excision of the lesion
and curettage, though one case involved excision with Er-
YAG Laser [18].
The cases of PGCG were treated with a number of
different strategies. In all of the cases the lesion was surgically
removed, but in addition to this, in nine cases curettage
was also performed [2, 4, 8, 9, 11, 14, 21], in two cases the
prosthesis was replaced [10, 11], in one case the prostheses
were temporarily removed [15], in another case a graft was
performed [13], and in four cases the implant was explanted
[2, 5, 12] (Table 2).
The 6 cases which suffered relapse all were PGCG. Three
of these were treated with excision and curettage only [2, 9,
12], while the other 3 also underwent explantation [2, 8, 12]
(Table 2). In fact, from the ones that underwent explantation,
one had a PGCGwith 8 times of recurrence [12] and the other
case which had three times [2] was treated with curettage [2].
3.1. Case Report: Pyogenic Granuloma. A 52-year-old male
came for consultation reporting two swellings intraorally
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Table 2: Most highlighted characteristics from published cases of PG and PGCG associated with implants.
Author (year) Sex Age Localization Bone loss Final treatment Relapse Follow-up(months) PG/PGCG
Hanselaer et al. (2010)
[9] F 34 Posterior maxilla No Excision + curettage 1 8 PGCG
M 31 Posterior mandible Yes Excision + curettage 1 — PGCG
Hirshberg et al.
(2003) [12] F 69 Anterior maxilla No Excision + explantation 1 — PGCG
M 44 Posterior mandible Yes Excision + explantation 8 — PGCG
Bischof et al. (2004)
[10] F 56 Posterior mandible No
Excision + new prosthesis +
control of plaque No 36 PGCG
Scarano et al. (2008)
[13] F 48 Posterior maxilla Yes Excision + soft tissue graft No — PGCG
Cloutier et al. (2007)
[5] M 21 Posterior mandible Yes Excision + explantation No 12 PGCG
F 62 Posterior mandible Yes Excision + curettage No 2 PGCG
Hernández et al.
(2009) [2] F 45 Posterior mandible Yes Excision + curettage 5 108 PGCG
F 36 Posterior maxilla Yes Excision + explantation 3 12 PGCG
Ozden et al. (2009)
[11] F 60 Posterior mandible Yes Excision + new prosthesis No 12 PGCG
Olmedo et al. (2010)
[14]
F 64 Anterior maxilla Yes Excision + curettage No 24 PGCG
F 75 Posterior mandible No Excision + curettage No 48 PG
Dojcinovic et al.
(2010) [4] M 32 Posterior maxilla No Excision + curettage No 18 PG
Peñarrocha-Diago et
al. (2012) [15] F 54 Posterior mandible Yes
Excision + curettage +




al. (2013) [16] M 74 Anterior maxilla No Excision No 6 PGCG
Etöz et al. (2013) [17] M 55 Posterior mandible No Excision + curettage No 8 PG
Kaya et al. (2013) [18] M 39 Posterior mandible No Excision with an Er-YAGLaser No 6 PG
Kang et al. (2014) [19] M 68 Posterior maxilla No Excision + curettage No 12 PG
Trento et al. (2014)
[20] F 33 Posterior mandible No Excision + curettage No 6 PG
Brown et al. (2015)
[21] F 46 Posterior mandible No Excision + curettage No 6 PGCG
M: male; F: female; PG: pyogenic granuloma; PGCG: peripheral giant-cell granuloma.
adjacent to implants that had been placed three years earlier.
These lesions had developed over 6 months and were not
painful but did bleed on brushing.With regard to his medical
history, of interest, he was diagnosed with antiphospholipid
syndrome in 2001 and suffered an acute myocardial infarc-
tion in August 2011. He also suffered from focal segmental
glomerulosclerosis and chronic kidney failure since 2010 but
did not require hemodialysis and could be linked to systemic
lupus erythematosus. With respect to his dental history,
he suffered from advanced chronic generalized periodontal
disease and had plaque and calculus deposits both supra- and
subgingivally. Due to his advanced periodontal disease the
remaining upper and lower teeth had been splinted two years
earlier.
The patient’s regular medicines included 4mg aceno-
coumarol, 100mg acetylsalicylic acid, pantoprazole 40mg
(proton pump inhibitors), atorvastatin 40mg (HMG-CoA
reductase inhibitors), amlodipine (calcium channel block-
ers), bisoprolol 5mg (beta-blocker), and 360mgmycopheno-
lic acid. No habits of substance abuse were reported.
Oral examination revealed two nodular erythematous
sessile lumps of 1.5 cm diameter, with elastic consistency and
granulomatous appearance. They were associated with the
gingiva, located on the buccal and palatal/lingual sides of
implants 3.6, 1.6, and 1.7 (Figure 1). Radiographic investiga-
tion revealed 5mm of peri-implant bone loss associated with
both lesions.The presumptive diagnosis was that of pyogenic
granuloma or peripheral giant-cell granuloma. An excisional
biopsy was performed along with curettage and irrigation
with chlorhexidine 0.5% of both the surgical site and the
exposed implant threads. The microscopic description was
that of ulcerated lesions covered by a fibrin and leukocyte




Figure 1: (a) Exophytic granulomatous lesion in 16 and 17 implants. (b) Palatal view of the granulomatous lesion in 16 and 17. (c) Granulo-
matous lesion in 36.
membrane and made up of granulation tissue with a mixed
inflammatory infiltrate with polymorphonuclears, together
with vascular proliferation (Figure 2). Squamous epithelium
with parakeratosis, dyskeratosis, acanthosis, and elongation
of the epithelial peaks was observed at the far extremes. The
epithelial maturation was conserved and no dysplasia-like
phenomenonwas observed.The results were compatible with
a diagnosis of pyogenic granuloma, without any suggestion
of malignancy. Postoperatively there were no further issues
and there was no evidence of relapse at 12-month follow-up
(Figure 3).
3.2. Case Report: Peripheral Giant-Cell Granuloma. A 64-
year-old male came for consultation regarding a 15-day
history of an exophytic mass associated with the buccal
marginal gingiva of an implant supported dental prosthesis
in the lower right quadrant. This had been placed 8 years
earlier.The lesionwas asymptomatic, but the patient reported
bleeding on brushing.
The patient’s medical history revealed complete atri-
oventricular block, coronary atherothrombosis with acute
myocardial infarction in 2006, left ventricular dysfunction,
pericarditis, and diabetes mellitus type 2. The patient’s
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Figure 2: (a) Periapical radiograph that shows bone loss in implants 16 and 17. (b) Periapical radiograph that shows bone involvement in
implant 36.
regular medicines included carvedilol 6.25mg, 1/day (beta-
blocker), enalapril 5mg, 1/day (ACE inhibitor), furosemide
40mg, 1/day (sulphonamide), Tromalyt 150mg, 1/a day
(acetylsalicylic acid), omeprazole 20mg, 1/day (proton pump
inhibitors), and variable dosage of insulin. No habits of
substance abuse were reported. With respect to the patient’s
dental history, he was partially dentate in the mandible as
a result of periodontal disease and had multiple implant
supported fixed prostheses, with a total of 10 implants placed
8 years earlier.
On examination intraorally there was a swelling of 1 cm
diameter on the buccal surface of implant 4.6. The lesion was
reddish-purple in color and was well defined with an elastic
consistency and an irregular texture. It was not mobile and
was sessile. Periapical radiograph revealed bone loss of 4mm
affecting both the mesial and distal surfaces of the implant
(Figure 4).
Histopathology confirmed that it was an ulcerated
peripheral giant-cell granuloma,without suggestion ofmalig-
nancy (Figure 5). Histologically it was described as a lesion
covered by a parakeratinized stratified squamous epithelium,
with areas of atrophy and ulceration in its thickness. A dense
proliferation of multinucleated giant cells was dispersed on
a stroma of the tissue, which was highly vascularized, with
areas of hemorrhage, deposits of hemosiderin, and infiltrate
due to accumulation of lymphoplasmacytic inflammatory
cells. Laboratory tests showed no abnormalities with regard
to calcium/phosphatemetabolism or parathyroid gland func-
tion.
Treatment involved complete excision of the lesion, curet-
tage of the exposed implant threads, and irrigation with
chlorhexidine 0.5%. Postoperative healing was good and at
12-month follow-up there was no evidence of recurrence
(Figure 6).
4. Discussion
Peri-implantitis with progressive bone loss is reported to be
the most frequent complication associated with implants [2].
Its treatment is challenging and to do so correctly we must
identify the pathology leading to peri-implantitis [2]. In our
view recognition of the soft tissue pathology by biopsy should
be the first step for potential successful treatment.
The etiology of these conditions when associated with
implants is similar to that which is described when they are
associated with teeth, where factors such as trauma, plaque
deposits, or chronic infection have a major role [1]. In cases
associated with implants, incorrect or inadequate prosthesis
(implant cap or healing cap, poorly adjusted suprastructures,
etc.) is also considered to be a possible causative factor [2, 9].
With regard to inadequate prosthesis, Bischof et al. [10],
Ozden et al. [11], andPeñarrocha-Diago et al. [15] replaced the
prosthesis or temporarily removed the prosthesis, allowing
for better plaque control, and they reported no recurrence.
Another suggested potential cause, although controversial,
is that an inflammatory response to titanium may lead to
development of granulomas [10, 12–15, 22].
The clinical presentation and age group of the PG
and PGCG cases described appeared to be similar when
associated with teeth [23–27]. Our data collection showed
PGCG is more frequent in women and in the posterior
mandible [2]. One could propose this may be due to greater
plaque accumulation posteriorly due to difficult access for
thorough oral hygiene. When associated with teeth, PG is
also commonly seen in females [1, 2]. This is in contrast
with our findings which suggest that when associated with
implants it is more prevalent in men. Nonetheless this may
be an inaccurate conclusion and due to the small number of
cases reported.
In females, pregnancy can have a role in this condition.
It has been suggested that the increase of estrogen and pro-
gesterone can influence gingival physiology, enhancing the
tissue response to the local microbiota, with a predominance
of more pathogenic microorganisms [20, 27, 28].
Data from the selected articles suggests that bone loss
from the implant site is more commonly associated with
PGCG [2, 5, 11–15] than PG. Hernández et al. [2], Cloutier
et al. [5], and Bischof et al. [10] support the hypothesis that
bone loss occurs first, exposing the implant collar, which then
contributes to irritating factors that lead to PGCG.This is also
more prevalent when lesions present posteriorly. Again this
could be related to difficult access for thorough oral hygiene
though this may also be due to the greater occlusal load
experienced posteriorly, as opposed to that experienced by
the anterior teeth [2, 5, 10].




Figure 3: (a) 12-month postexcision follow-up of the lesion in 16 and 17 area. (b) Palatal view of the 12-month postexcision follow-up of the
lesion in 16 and 17. (c) 12 month postexcision follow-up of the lesion in 36.
The prevalence of recurrence in cases of PG and PGCG
is estimated to be 2.9–8.2% and 5–11%, respectively, but in
cases associated with implants these figures increase [2, 9,
16, 17, 21]. Recurrence has been reported in 6 of the 15
published cases of PGCG associated with implants (Table 2).
Lester et al. [23], in a review of 279 cases, noted a total
of 10 recurrences on 5 implant cases; 1 implant case had 2
recurrences, and another case with multiple implants had
8 recurrences. It was noted that while 2 of the 5 implant
cases (40%) had multiple recurrences, 6 of 237 non-implant-
related cases (2.5%) presented with multiple recurrences
too. Several possible explanations are considered, such as
incomplete excision, but in addition these lesions may have
been caused by combination of irritating factors, which
therefore makes it challenging to eradicate all possible causes
[2, 5, 8].
Several treatments have been described when treating
PG/PGCG when associated with implants, with excision
and curettage being the most common. This is consistent
with normal convention when these lesions are associated
with teeth (being a relatively simple technique and with
satisfactory results [1, 2, 9, 10, 12, 25, 26, 29]).
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Figure 4: (a) Exophytic granulomatous lesion in 4.6. (b) Periapical radiograph that shows bone involvement in implant 46.
Figure 5: Histopathology of peripheral giant-cell granuloma.
Other options have been described such as the use of
Er-YAG Laser [18] or explantation of the implant and the
provision of a new prosthesis [10, 11] or indeed temporary
removal [15]. It is suggested that use of the Er-YAG Laser
for granuloma excision offers advantages in comparison to
conventional surgery techniques, especially by reducing the
risk of bleeding, pain, and postoperative edema and also
eliminating the need for sutures at the end of the procedure
[18].
Given the small number of cases published, it is difficult
to evaluate if explantation of the implant affects the number
of recurrences or the amount of bone loss. Recurrences of
PG and PGCG have been described when associated with
bad plaque control but also due to hormonal imbalance
during pregnancy, especially in PG cases [30]. The authors
believe that more aggressive treatments such as explanation
can be used as a secondary technique, only after excision
and curettage have failed as explantation could be beneficial
in improving plaque control and consequently reduce the
number of relapses and amount of bone loss. However the
data available about its use in implants is still limited. The
use of antimicrobials such as chlorhexidine, as described in
our cases, is reported to offer improved plaque control in the
treatment of peri-implantitis [29].
5. Conclusion
In conclusion, we believe the primary approach to manage
these two soft tissue conditions should be excisional biopsy
and subsequent histopathology. The authors believe oral
hygiene instruction should be one of the first steps in man-
agement as good plaque control could help reduce number
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Figure 6: 12-month postexcision follow-up of the lesion located in
46.
of recurrences. This review of the literature highlights that
histopathological diagnosis is important, as if PGCG is
diagnosed histologically, then the clinician will be aware of a
higher risk of bone loss and higher rate of recurrence. This
would highlight the need of close monitoring and regular
review. However, we recognize the limitations of this analysis
due to the limited number of case reports published and
consequently these conclusions should be interpreted with
caution. Further cohort studies with representative sample
sizes, control group, and standard outcome measures are
necessary.
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